Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue

HIV Clinical Trials

Volumn 13, Issue 2, 2012, Pages 103-110

  Vrouenraets, S M E ^a,b   Wit, F W N M ^a,b   Garcia, E Fernandez ^c   Huber, M ^d   Brinkman, K ^e   Moyle, G ^f   Domingo, P ^g   Tarr, P E ^h   Podzamczer, D ⁱ   Ristola, M ^j   Gatell, J M ^k   Livrozet, J M ^l   Furrer, H ^m   Reiss, P ^a,b  

^a AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c IATEC BV   (Netherlands)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^f CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h UNIVERSITY OF BASEL   (Switzerland)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^k HOSPITAL CLÍNIC   (Spain)

^l EDOUARD HERRIOT HOSPITAL   (France)

^m UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

AZT; body composition; NNRTI; PI

Indexed keywords

ATAZANAVIR; FOSAMPRENAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

ADULT; ARTICLE; BODY COMPOSITION; BODY MASS; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EXPOSURE; DUAL ENERGY X RAY ABSORPTIOMETRY; ETHNICITY; FEMALE; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAABDOMINAL FAT; LEG; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIDE EFFECT; SUBCUTANEOUS FAT; TREATMENT DURATION;

ANTI-HIV AGENTS; BODY COMPOSITION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; SUBCUTANEOUS FAT; ZIDOVUDINE;

EID: 84859814578     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1302-103     Document Type: Article

References (14)

1. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: Results of a substudy from a comparative trial. AIDS. 2002;16(18):2447-2454.
2. van Vonderen MG, van Agtmael MA, Hassink EA, et al. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS One. 2009;4(5):e5647.
3. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17(7):971-979.
4. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14(10):1309-1316.
5. Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005;19(16):1807-1818.
6. Dube MP, Komarow L, Mulligan K, et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr. 2007;45(5):508-514.
7. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23(9):1109-1118.
8. Moyle G, Fisher M, Sweet Study Group. Factors associated with low limb fat in a cohort of zidovudine-treated subjects. Antiviral Ther. 2007;12(suppl 2):L28.
9. McComsey G, Rightmire A, Wirtz V, Yang R, Mathew M, McGrath D. Changes in body composition with ritonavirboosted and unboosted atazanavir treatment in combination with lamivudine and stavudine: A 96-week randomized, controlled study. Clin Infect Dis. 2009;48(9):1323-1326.
10. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatmentnaive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47(1):74-78.
11. Brown TT, Xu X, John M, et al. Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIVuninfected controls: A substudy of the Multicenter AIDS Cohort Study. AIDS Res Ther. 2009;6:8.
12. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003;32(1):48-56.
13. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005;40(2):121-131.
14. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2010 rev. http://www.who.int/ hiv/pub/arv/adult2010/en/index.html